Stay updated on Pembrolizumab for HNSCC Residual Disease Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for HNSCC Residual Disease Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A banner was added announcing NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T23:09:53.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The site footer revision number changed from v3.7.1 to v3.7.2; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T23:36:03.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The footer site revision changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T23:28:59.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, making the study record inaccessible. The prior study documents and related navigation have been removed, leaving only the error message and site footer.
    Difference
    19%
    Check dated 2026-09-19T22:23:40.000Z thumbnail image
  5. Check
    62 days ago
    Change Detected
    Summary
    The page’s revision label was updated from v3.6.5 to v3.6.6, indicating a minor version update in the page documentation.
    Difference
    0.1%
    Check dated 2026-08-29T18:59:59.000Z thumbnail image
  6. Check
    82 days ago
    Change Detected
    Summary
    Revision updated from v3.6.4 to v3.6.5, indicating a small internal release update to the page's versioning metadata.
    Difference
    0.1%
    Check dated 2026-08-08T22:27:50.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for HNSCC Residual Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.